<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127714">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01854775</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-292-0106</org_study_id>
    <secondary_id>2013-002780-26</secondary_id>
    <nct_id>NCT01854775</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents</brief_title>
  <official_title>A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to confirm the dose and evaluate the pharmacokinetics, safety, tolerability,
      and antiviral activity of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
      (E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected, antiretroviral (ARV) treatment
      naive adolescents. Antiviral activity will be determined by the achievement of HIV-1 RNA &lt;
      50 copies/mL at Weeks 24 and 48.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK) parameter of EVG as measured by AUCtau and PK parameter of TAF as measured by AUClast</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)
AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent serious adverse events and all treatment-emergent adverse events</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Treatment-emergent serious adverse events and adverse events will be summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with plasma HIV-1 RNA &lt; 50 copies/mL</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with plasma HIV-1 RNA &lt; 400 copies/mL</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma log10 HIV-1 RNA (copies/mL)</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ cell count (cells/Î¼L) and percentage</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of EVG as measured by Ctau, Cmax, apparent clearance, and apparent Vz, PK parameters of TAF as measured by Cmax, apparent clearance, and apparent Vz, and PK parameters of FTC, tenofovir (TFV), and COBI as measured by AUCtau, Cmax, and Ctau</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval
Cmax is defined as the maximum observed concentration of drug in plasma
Vz is defined as the volume of distribution of the drug
AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acquired Immune Deficiency Syndrome (AIDS)</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>E/C/F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive E/C/F/TAF STR once daily with food</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E/C/F/TAF</intervention_name>
    <description>E/C/F/TAF STR tablets contain 150 mg of elvitegravir (EVG), 150 mg of cobicistat (COBI), 200 mg of emtricitabine (FTC), and 10 mg of tenofovir alafenamide (TAF; as 11.2 mg of TAF fumarate)</description>
    <arm_group_label>E/C/F/TAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following inclusion criteria to be eligible for
        participation in this study. Subjects with screening results that do not meet eligibility
        criteria will not be allowed to rescreen:

          -  12 years to &lt; 18 years of age at Baseline

          -  Weight greater than or equal to 35 kg (77 lbs)

          -  Subjects able to give written assent prior to any screening evaluations

          -  Parent or guardian able to give written informed consent prior to any screening
             evaluations and willing to comply with study requirements

          -  Plasma HIV-1 RNA levels of &gt; 1,000 copies/mL at Screening (Roche COBAS TaqMan v2.0)

          -  CD4+ cell count &gt; 100 cells/microliter

          -  Screening genotype report shows sensitivity to EVG, FTC and TFV

          -  Adequate renal function

          -  Clinically normal ECG

          -  Documented screening for active pulmonary tuberculosis per local standard of care
             within 6 months of a Screening visit.

          -  Hepatic transaminases less than or equal to 5 x upper limit of normal

          -  Total bilirubin less than or equal to 1.5 mg/dL, or normal direct bilirubin

          -  Adequate hematologic function

          -  No prior use of any approved or experimental anti-HIV-1 drug for any length of time

          -  Negative serum pregnancy test

          -  Females of childbearing potential must agree to utilize highly effective
             contraception methods or be non-heterosexually active or practice sexual abstinence
             from Screening throughout the duration of study treatment and for 30 days following
             discontinuation of investigational medicinal product.

          -  Female subjects who utilize hormonal contraceptive as one of their birth control
             methods must have used the same method for at least three months prior to study
             dosing.

          -  Male subjects must agree to utilize highly effective contraception methods during
             heterosexual intercourse or be non-heterosexually active, or practice sexual
             abstinence from Baseline throughout the study period and for 30 days following
             discontinuation of investigational medicinal product.

          -  Able to swallow oral tablets

          -  Must be willing and able to comply with all study requirements

          -  Life expectancy &gt; 1 year

        Exclusion Criteria:

        Subjects who meet any of the following exclusion criteria are not to be enrolled in this
        study.

          -  A new AIDS defining condition diagnosed within the 30 days prior to Screening

          -  Positive Hepatitis C antibody

          -  Positive Hepatitis B surface antigen or other evidence of active hepatitis B virus
             infection.

          -  Prior treatment with any approved or investigational or experimental anti HIV-1 drug
             for any length of time

          -  Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months
             of the Screening visit.

          -  Anticipated to require rifamycin treatment for mycobacterial infection while
             participating in the study.

          -  Subjects experiencing decompensated cirrhosis

          -  Pregnant or lactating subjects

          -  Have an implanted defibrillator or pacemaker

          -  Have any serious or active medical or psychiatric illness which, in the opinion of
             the Investigator, would interfere with subject treatment, assessment, or compliance
             with the protocol.

          -  Current alcohol or substance abuse judged by the Investigator to potentially
             interfere with subject compliance.

          -  Have history of significant drug sensitivity or drug allergy.

          -  Known hypersensitivity to the study drugs, the metabolites or formulation excipients

          -  Have been treated with immunosuppressant therapies or chemotherapeutic agents within
             3 months of study Screening or expected to receive these agents during the study

          -  A history of malignancy within the past 5 years (prior to Screening) or ongoing
             malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or
             resected, non-invasive cutaneous squamous carcinoma.

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 30 days prior to Baseline.

          -  Have previously participated in an investigational trial involving administration of
             any investigational agent within 30 days prior to the study dosing.

          -  Participation in any other clinical trial without prior approval from sponsor is
             prohibited while participating in this trial.

          -  Subjects receiving ongoing therapy with any of the medications in the table below,
             including drugs not to be used with EVG, COBI, FTC, tenofovir disoproxil fumarate
             (TDF) and TAF; or subjects with any known allergies to the excipients of E/C/F/TAF
             STR tablets.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Bennett, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Skanda Goudar</last_name>
    <phone>650-524-4274</phone>
    <email>skanda.goudar@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Miller's Children Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>562-933-8590</phone>
    </contact>
    <investigator>
      <last_name>Jag Batra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>510-869-8400</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Burack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>303-724-3447</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth McFarland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>202-476-2083</phone>
    </contact>
    <investigator>
      <last_name>Natella Rakhmanina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida - Department of Pediatrics</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-259-8800</phone>
    </contact>
    <investigator>
      <last_name>Carina Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-727-4972</phone>
    </contact>
    <investigator>
      <last_name>Rana Chakraborty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-263-6513</phone>
    </contact>
    <investigator>
      <last_name>William Borkowsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>315-464-6331</phone>
    </contact>
    <investigator>
      <last_name>Leonard Weiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coleen Cunningham, MD</last_name>
      <phone>919-668-4851</phone>
    </contact>
    <investigator>
      <last_name>Coleen Cunningham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>901-495-5067</phone>
    </contact>
    <investigator>
      <last_name>Aditya Gaur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Gualdalajara Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+021 650 6726</phone>
    </contact>
    <investigator>
      <last_name>Catherine Orell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Be Part Yoluntu Centre</name>
      <address>
        <city>Cape Town</city>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+021868399012</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth Hellstrom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mpati Medical Centre</name>
      <address>
        <city>Dundee</city>
        <zip>3000</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+011 27-342182092</phone>
    </contact>
    <investigator>
      <last_name>Jan Fourie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gulam Latiff Private Practice</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+011 27 31 309 3245</phone>
    </contact>
    <investigator>
      <last_name>Gulam Latiff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical HIV Research Unit</name>
      <address>
        <city>Johannesburg</city>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+011-2711 276 8800</phone>
    </contact>
    <investigator>
      <last_name>Mohammed Rassool</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rahima Moosa Mother and Child Hopsital</name>
      <address>
        <city>Johannesburg</city>
        <zip>2112</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+011 27 11 470 9168</phone>
    </contact>
    <investigator>
      <last_name>Renate Strehlau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+011-27-11-989-9700</phone>
    </contact>
    <investigator>
      <last_name>Avy Violari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The HIV Netherlands Australia Thailand Research collaboration (HIV-NAT)</name>
      <address>
        <city>Pathumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>02 652 3040</phone>
      <phone_ext>134</phone_ext>
    </contact>
    <investigator>
      <last_name>Wasana Pasitsuebsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Faculty of Medicine, Khon Kaen University</name>
      <address>
        <city>Muang</city>
        <state>Khon Kaen</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>043 34 88 32</phone>
    </contact>
    <investigator>
      <last_name>Pope Kosalaraksa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Savang Vadhana Memorial Hospital</name>
      <address>
        <city>Chonburi</city>
        <zip>20110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+66 383 255 90</phone>
    </contact>
    <investigator>
      <last_name>Wicharn Luesomboon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Centre</name>
      <address>
        <city>Lubowa Hill</city>
        <state>Kampala</state>
        <zip>PO Box 10005</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+256414201148</phone>
    </contact>
    <investigator>
      <last_name>Hilda Kizito, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescents</keyword>
  <keyword>HIV-1</keyword>
  <keyword>HIV</keyword>
  <keyword>Treatment-naive</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
